| 21 Janvier 2011
Pluristem Conference Call to Discuss Granting of Approval From FDA-EMA for Phase II/III Clinical Trial for Treatment of Critical Limb Ischemia
· Who: Pluristem Therapeutics Inc. (Nasdaq: PSTI; TASE: PLTR), has been approved for a parallel scientific advisory process with the FDA and EMA regarding the Company’s planned clinical development for its PLX-PAD cells for the treatment of Critical Limb Ischemia (CLI) and a Phase II study for Intermittent Claudication (IC).
· What: Conference call with CEO Zami Aberman, CFO Yaky Yanay and VP Corporate Development Dr. Bill Prather, who will discuss the latest in their interactions with both the U.S. FDA and Europe ’s EMA, as well as a look into the company's plans for moving ahead. A Q&A with participating journalists will follow.
· Why: Approval marks the first time a company will be able to offer preventative treatment of Peripheral arterial disease (PAD). The combined annual market for treatment of CLI and IC is more than 20 million patients and $14 billion worldwide.
· When: Wednesday, January 19 at 10:30 am ET
· How:
o From the US , dial: 1-877-941-8609 or 1-480-629-9031 and then enter the conference ID: 4403197
o International Dial In: +1-480-629-9031 and then enter the conference ID: 4403197
